| Literature DB >> 25556055 |
G Baaklini1, V Dupray2, G Coquerel2.
Abstract
The present study focuses on the ability of excipients to induce the crystallization of a specific polymorphic form of pyrazinamide (PZA) and more interestingly, to block the irreversible solid-solid transition of the metastable forms of the PZA to the stable form at room temperature. We outline an experimental protocol for the production of a structurally pure γ form of PZA by means of spray drying. Without any particular treatment, phase transition to δ form was detected after 14 days of storage under ambient conditions. In order to prevent this irreversible phase transition, different excipients were co-spray dried with PZA. By co-spray drying 5% in mass of 1,3-dimethylurea (DMU) with PZA, we noticed its ability in preventing phase transitions and thus to maintain PZA under its γ form up to 12 months of storage at room temperature. Raman spectroscopy evidenced how DMU crystals surround particles of γ PZA which suggest that DMU might interact with the surface of PZA particles, thus blocking the phase transition. On the other hand, the co-spray drying of PZA with the polymerpolyvinylpyrrolidone (PVP) resulted in the crystallization of δ form of PZA. The physical mixture was intact over 12 months of storage at room temperature.Entities:
Keywords: 1,1-Diethylurea (PubChem CID:12472); 1,3-Dimethylurea; 1,3-Dimethylurea (PubchemCID : 7293); Citric acid (PubChem CID: 311); Co-spray drying; Glycine (PubChem CID: 750); Physical stability; Polymorphic transition; Polyvinylpyrrolidone (PubChemCID: 11989721); Pyrazinamide; Pyrazinamide (PubChemCID: 1046); Sodium chloride (PubChem CID: 5234); Urea (PubChemCID: 1176); d-Mannitol (PubChem CID: 6251); l-Arginine (PubChemCID: 6322)
Mesh:
Substances:
Year: 2014 PMID: 25556055 DOI: 10.1016/j.ijpharm.2014.12.063
Source DB: PubMed Journal: Int J Pharm ISSN: 0378-5173 Impact factor: 5.875